BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 08, 2004
 |  BioCentury  |  Regulation

CMS listens

CMS listens

Issue OPPS proposed rule Comments to CMS OPPS CMS final rule
Orphan drugs Cover 12 orphan drugs per its definition. Requests that Campath alemtuzumab, Elitek rasburicase, Vidaza azacitadine, and Botox botulinum toxin be included as orphan drugs. Agreed to include Campath and Vidaza in orphan drug list (see "CMS Grows its Orphanage," A13).
Proposed to place a payment cap of 95% of AWP if payment based on 106% ASP would have exceeded 88% of AWP. Access may be compromised. In physician setting, same drugs not subject to 95% AWP cap. Dropped 95% cap. All orphan drugs will be paid at the higher of 106% of ASP or 88% of AWP.

Read the full 623 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >